I hereby certify that this correspondence is being transmitted via Electronic Filing System to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 9, 2006

PATENT

Oksana Buynitzky Date of Signature

exteler 9, 2006

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gonda et al.

Group Art Unit: Not Assigned

Serial No.: 10/550,533

Examiner: Not Assigned

Filed: September 23, 2005

Docket No.: 1386/21

For:

METHOD FOR IDENTIFYING NUCLEIC ACID MOLECULES ASSOCIATED

WITH ANGIOGENESIS

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the references listed on the attached form PTO-1449. Pursuant to 37 C.F.R. § 1.98(a)(2)(i), copies of the U.S. patents and U.S. patent application publication references A-D cited on the attached Form PTO-1449 are not attached. However, copies can be provided if necessary.

Attv. Docket No.: 1386/21

Applicants' undersigned attorney wishes to bring to the attention of the Patent and Trademark Office that reference WO Publication No. WO01/22920 was initially intended to be submitted, but due to the large size of the publication, US Publication No. US2003/0109690 A1, which is equivalent to the WO Publication No. WO01/22920, is instead cited in the Form PTO-1449.

Copies of the references E-L as well as Form PTO-1449 are attached hereto as electronic files in PDF format. The electronic files of references E-L were divided into several parts to reduce the size of the attached files:

- 1. Reference E (EP 1396543) was broken into 3 parts;
- 2. Reference F (WO01/57273) was broken into 3 parts;
- 3. Reference G (WO01/57274) was broken in 2 parts:
- 4. Reference H (WO01/64835) was broken into 5 parts;
- 5. Reference I (WO01/92581) was broken into 2 parts;
- 6. Reference J (WO02/14500) was broken into 3 parts;
- Reference K (WO02/053774) was broken into 2 parts;
- 8. Reference L (WO02/083898) was broken into 2 parts.

This is not to be construed as a representation that a search has been made or that a reference is relevant merely because cited.

Early passage of the subject application to issue is earnestly solicited.

Atty. Docket No.: 1386/21

The Commissioner is hereby authorized to charge any fees associated with the filling of this correspondence to Deposit Account No. <u>50-0426</u>.

Respectfully submitted,

JENKINS, WILSON, TAYLOR & HUNT, P.A.

Date: October 9, 2006

Arles A. Taylor, Jr.

Registration No. 39,395

Customer No.: 52354

1386/21

AAT/JD/omb

**Enclosures** 

FORM PTO-1449 U.S. Department of Commerce	Application No.:	10/550,533
Patent and Trademark Office	Filing Date:	September 23, 2005
List of Decuments Cited by Applicant	First Named Inventor:	Gonda Thomas John
List of Documents Cited by Applicant	Group:	TBA
	Examiner:	TBA
Page 1 of 2	Attorney Docket No.:	1386/21

				_ <u></u>		
			U.S. PATENT D	OCUMENTS		
Examin er Initials	Cite No.	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Colur Lines, whe relevant pass or relevant fig appear	re ages
	А	US2003/109690 A1	06/12/2003	Human Genome Sciences, Inc.		
	В	US 5,597,707	01/28/1997	Bristol-Myers Squibb Company		× ± +-
	С	US 5,354,847	10/11/1994	Bristol-Myers Squibb Company		
	D	US 6,569,662	05/27/2003	Hyseq, Inc.		- ) - 1
		FC	OREIGN PATENT	DOCUMENTS		4 4 2:
Examin er Initials	Cite No.	Document Number (country code, no., kind code (if known)	Publication Date	Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	T
	E	EP 1396543	03/10/2004	Research Association for Biotechnology, Tokyo		
	F	WO 01/57273	08/09/2001	MOLECULAR DYNAMICS		
	G	WO 01/57274	08/09/2001	MOLECULAR DYNAMICS		

EXAMINER	DATE CONSIDERED

<sup>\*</sup>Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	nark Office Cited by Applicant		Filing Date: First Named Inventor:	September 23,		
ments	Cited by Applicant			Gonda Thomas	lohe	
ments	Cited by Applicant				omas John	
			Group: TBA			
	Page 2 of 2	Attorney Docket No.:	1386/21			
					T	
Н	WO 01/64835	09/07/2001	HYSEQ, Inc.			
I	WO 01/92581	12/06/2001	CORIXA Corporation			
J	WO 02/14500	02/21/2002	CHIRON Corporation; HYSEQ, Inc.			
K	WO 02/053774	07/11/2002	Henkel Kommanditgesellschaft AUF AKTIEN			
L	WO 02/083898	10/24/2002	GENSET			
	1					
		OTHER DO	CUMENTS			
Cite No.	Include Author (in	CAPITAL LETTEF	RS), Title, Journal, Date, Pert	inent Pages, Etc.	T	
-	J K L	WO 01/92581  J WO 02/14500  K WO 02/053774  L WO 02/083898  Cite Include Author (in 6)	WO 01/92581 12/06/2001  J WO 02/14500 02/21/2002  K WO 02/053774 07/11/2002  L WO 02/083898 10/24/2002  OTHER DO  Cite Include Author (in CAPITAL LETTER	WO 01/92581         12/06/2001         CORIXA Corporation           J         WO 02/14500         02/21/2002         CHIRON Corporation; HYSEQ, Inc.           K         WO 02/053774         07/11/2002         Henkel Kommanditgesellschaft AUF AKTIEN           L         WO 02/083898         10/24/2002         GENSET           OTHER DOCUMENTS           Cite         Include Author (in CAPITAL LETTERS), Title, Journal, Date, Pert	WO 01/92581   12/06/2001   CORIXA Corporation	

EXAMINER	DATE CONSIDERED

<sup>\*</sup>Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.